Anlon Healthcare Ltd

Anlon Healthcare Limited was originally incorporated as 'Anlon Ventures Private Limited', dated November 19, 2013 issued by the RoC. The Company changed the name from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited' and a fresh Certificate of Incorporation dated May 27, 2015 was issued by the RoC. The status of the Company was subsequently converted to a Public Limited and the name of the Company was changed to 'Anlon Healthcare Limited' dated September 2, 2024 by the RoC. Anlon Healthcare is engaged in manufacturing of Pharma Intermediates and APIs. They are one of the few manufacturers of loxoprofen sodium dihydrate in India, a notable API , widely used in treatment of pain/inflammation association with conditions including rheumatoid arthritis, osteoarthritis, lower back pain, frozen shoulder, neck-shoulder-arm syndrome, tooth pain or after surgery, injury or tooth extraction. It serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula (FDF) such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. In addition to manufacturing of Pharma Intermediate and APIs in accordance with various domestic and international standards, the Company has recently started undertaking custom manufacturing services for complex or novel chemical compounds. The Company started commercial production of Pharma Intermediate and API in 2018. It work out manufacturing activities at Rajkot, Gujarat, which comprise of two separate manufacturing blocks for manufacturing of Pharmaceutical Intermediate and APIs respectively with an aggregate installed production capacity of 400 MTPA. The Company launched the Initial Public Offering of 1,33,00,000 equity shares having the face value of Rs 10, by raising funds aggregating to Rs 121.03 Cr via fresh issue in August 2025.